{'fraction_non_alphanumeric': 0.03006012024048096, 'fraction_numerical': 0.01603206412825651, 'mean_word_length': 5.756756756756757, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Myositis associated with interleukin‐2 therapy in a patient with metastatic renal cell carcinoma

Background. Interleukin‐2 (IL‐2) has been used successfully in the treatment of some patients with metastatic renal cell carcinoma and melanoma, with a partial response rate of 15%–20%. It produces a well documented spectrum of side effects. Autoimmune diseases have been associated with IL‐2 immunotherapy and the development of autoimmune thyroiditis may correlate with anti‐tumor clinical response.